Related Experiment Videos
Evolution of drugs that preserve renal function.
1Rush Hypertension/Clinical Research Center, Department of Preventive Medicine, Rush Presbyterian/St. Luke's Medical Center, Chicago, Illinois, USA.
Journal of Clinical Pharmacology
|September 7, 2000
Summary
Advances in managing kidney disease focus on lowering blood pressure and proteinuria. Certain antihypertensive drugs that reduce proteinuria also lower cardiovascular risk, offering hope for slowing disease progression.
Area of Science:
- Nephrology
- Cardiovascular Medicine
- Pharmacology
Background:
- Renal disease progression has been a significant health concern over the last 50 years.
- Advances in treatment have focused on achieving lower blood pressure goals and reducing proteinuria.
Observation:
- Not all antihypertensive drug classes effectively lower proteinuria.
- Direct-acting vasodilators, alpha-blockers, and dihydropyridine calcium antagonists are noted exceptions.
- Antihypertensive agents that reduce proteinuria are linked to reduced cardiovascular risk.
Findings:
- Achieving lower blood pressure and proteinuria levels is key to slowing renal disease.
- Specific antihypertensive agents that lower both blood pressure and proteinuria are crucial.
- Combinations of antihypertensive medications may offer additive proteinuria reduction for enhanced efficacy.
Implications:
- Understanding the role of specific antihypertensives in proteinuria reduction is vital for treatment strategies.
- Targeting proteinuria alongside blood pressure may mitigate cardiovascular risks in renal patients.
- Future advances, including pharmacogenetics, hold promise for reducing the incidence of dialysis.